SG11201910027YA - Bispecific antibody against ox40 and ctla-4 - Google Patents

Bispecific antibody against ox40 and ctla-4

Info

Publication number
SG11201910027YA
SG11201910027YA SG11201910027YA SG11201910027YA SG 11201910027Y A SG11201910027Y A SG 11201910027YA SG 11201910027Y A SG11201910027Y A SG 11201910027YA SG 11201910027Y A SG11201910027Y A SG 11201910027YA
Authority
SG
Singapore
Prior art keywords
international
medicon
lund
village
alligator
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Ellmark
Christina Furebring
Per Norlén
Niina Veitonmäki
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706915.4A external-priority patent/GB201706915D0/en
Priority claimed from GBGB1717958.1A external-priority patent/GB201717958D0/en
Priority claimed from GBGB1805873.5A external-priority patent/GB201805873D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of SG11201910027YA publication Critical patent/SG11201910027YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201910027Y 2017-05-02 2018-05-01 Bispecific antibody against ox40 and ctla-4 SG11201910027YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1706915.4A GB201706915D0 (en) 2017-05-02 2017-05-02 Novel polypeptides
GBGB1717958.1A GB201717958D0 (en) 2017-10-31 2017-10-31 Novel polypeptides
GBGB1805873.5A GB201805873D0 (en) 2018-04-09 2018-04-09 Novel polypeptides
PCT/EP2018/061084 WO2018202649A1 (en) 2017-05-02 2018-05-01 Bispecific antibody against ox40 and ctla-4

Publications (1)

Publication Number Publication Date
SG11201910027YA true SG11201910027YA (en) 2019-11-28

Family

ID=62186395

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910027Y SG11201910027YA (en) 2017-05-02 2018-05-01 Bispecific antibody against ox40 and ctla-4

Country Status (12)

Country Link
US (1) US20200048358A1 (ru)
EP (1) EP3619236A1 (ru)
JP (1) JP2020518622A (ru)
KR (1) KR20200002889A (ru)
CN (1) CN110709421A (ru)
AU (1) AU2018262156A1 (ru)
BR (1) BR112019023097A2 (ru)
CA (1) CA3061549A1 (ru)
MX (1) MX2019012953A (ru)
RU (1) RU2019138067A (ru)
SG (1) SG11201910027YA (ru)
WO (1) WO2018202649A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107815465B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP3880247A4 (en) * 2018-11-13 2022-10-26 JN Biosciences, LLC BISPECIFIC ANTIBODIES TO ACTIVATE IMMUNE CELLS
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
BR112022007219A2 (pt) * 2019-10-17 2022-07-05 Univ Minnesota Sequências de fragmento de anticorpo clec12a e métodos
EP4047021A4 (en) * 2019-10-17 2023-11-22 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC OX40/PD1-L1 ANTIBODIES
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
KR20220124718A (ko) 2020-01-07 2022-09-14 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
CN115461371A (zh) * 2020-06-30 2022-12-09 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
CN114085376B (zh) * 2021-12-02 2022-12-20 中国科学院长春应用化学研究所 一种多肽及其制备方法、双特异性抗体及其应用
WO2023109900A1 (en) * 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
WO2023109901A1 (en) * 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
WO2023143478A1 (en) * 2022-01-27 2023-08-03 Crown Bioscience Inc. Novel anti-cd4 and anti-pd-l1 bispecific antibodies
WO2023143597A1 (en) * 2022-01-30 2023-08-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ctla4/ox40 bispecific antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
EA035266B1 (ru) * 2014-02-28 2020-05-22 Икнос Сайенсиз Са Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
MX2017014699A (es) * 2015-05-21 2018-04-11 Alligator Bioscience Ab Polipeptidos novedosos.

Also Published As

Publication number Publication date
WO2018202649A1 (en) 2018-11-08
JP2020518622A (ja) 2020-06-25
CN110709421A (zh) 2020-01-17
AU2018262156A1 (en) 2019-11-28
CA3061549A1 (en) 2018-11-08
BR112019023097A2 (pt) 2020-07-28
US20200048358A1 (en) 2020-02-13
RU2019138067A (ru) 2021-06-02
MX2019012953A (es) 2020-02-12
EP3619236A1 (en) 2020-03-11
KR20200002889A (ko) 2020-01-08

Similar Documents

Publication Publication Date Title
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201808990QA (en) Compositions for topical application of compounds
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908478SA (en) Sterilisation method
SG11201903636PA (en) Acoustic wave filter including two types of acoustic wave resonators
SG11201900634VA (en) Chimeric antigen receptor
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201809669RA (en) Use of glutamate modulating agents with immunotherapies to treat cancer
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201909949XA (en) Targeted immunotolerance
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201908088RA (en) Antibodies against pd-l1
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201900501RA (en) Cannabis composition
SG11201403402VA (en) Compounds
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407784UA (en) Engineered botulinum neurotoxin
SG11201407200TA (en) Liquid formulation